Feedback / Questions
ATV-1601 - Atavistik Bio
https://www.globenewswire.com/news-release/2025/08/04/3126441/0/en/Atavistik-Bio-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-ATV-1601-in-Patients-with-AKT1-E17K-mutant-Solid-Tumors.html
Aug 4, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next